Sponsor pipeline

Nuvalent Inc. clinical trial pipeline

Get alerts when Nuvalent Inc.'s trials change

4 active trials 4 recruiting 1 Phase 3 2 disease areas 1 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days

2026-08-26
Trial sites reduced: 37 → 30 locations
NCT06797362 Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC…

Active trials by phase

Phase 1
1
Phase 1/2
2
Phase 3
1

Active trials

NCT IDTitleConditionStatusUpdated
Phase 3
NCT06765109 Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC Non-small Cell Lung Cancer Recruiting 2026-08-25
Phase 1/2
NCT05384626 A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors… Locally Advanced Solid Tumor Recruiting 2026-05-27
NCT05118789 A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors… Locally Advanced Solid Tumor Recruiting 2025-10-24
Phase 1
NCT06521554 A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) Locally Advanced Solid Tumor Recruiting 2026-02-25

Disease areas by active trials

Non-Small Cell Lung Cancer (NSCLC) (1) · Lung Cancer (1)

Get alerts when Nuvalent Inc.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free